Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.
about
Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemiaItk phosphorylation sites are required for functional activity in primary T cells.Bruton's tyrosine kinase mediates FcγRIIa/Toll-like receptor-4 receptor crosstalk in human neutrophilsBruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.Divergent roles for macrophages in lymphatic filariasis.Splice-correction strategies for treatment of X-linked agammaglobulinemia.Tyrosine kinase Btk is required for NK cell activationReceptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitorsBruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.Ibrutinib for B cell malignancies.PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.BTK Signaling in B Cell Differentiation and Autoimmunity.Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease.A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition.Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man.Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.Flow cytometry assessment of intracellular BTK expression.Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis.Expression of Bruton's tyrosine kinase in B-cell neoplasms evaluated by flow cytometry.Enhanced Expression of Bruton's Tyrosine Kinase in B Cells Drives Systemic Autoimmunity by Disrupting T Cell Homeostasis.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
P2860
Q27634627-D248D749-5A99-4D7E-8457-177879057C46Q30164638-A098996C-7804-4BEE-8874-5CE70547E9B5Q30537877-690131B6-3172-44D1-99CD-5671FE9D6847Q33707566-C18DD0F5-FFAE-46C9-A7B5-8D844B7F49BDQ34319413-FCA5393E-DFD5-4D06-AB9A-E66518CCBA54Q35033817-44AEF7AD-57F2-431A-8434-2B10A84E4A12Q36078834-D557E432-4604-459D-8D31-F8BC3726F42EQ36329533-1671D6AC-BD89-4D58-99D7-11074C4A6A46Q36562876-42579A2F-94BE-4E71-8C2A-7158F483A659Q36799197-C52B2B6A-C9D2-4E6E-8498-E7C442A0049DQ37555418-5C5EDF57-9579-4267-BC5F-81D372582EC0Q37980900-4CB8F0F8-CF82-4B3B-8A1A-11CBE6E3238BQ38150876-3ABB7C97-4015-40A2-9F0C-2095EA9FA52AQ38581000-4F6394B6-774D-4BCF-B4C8-A9162FC22342Q38723944-852C4B22-B221-4D03-BCD7-91BE78A96CC9Q38988830-8F77EC94-8E7E-4832-BFE8-D18D7CE30944Q39024879-BC982E84-D518-41C6-A0C4-AE8FFDBBB944Q43562665-0065EFFD-DC88-41CB-BA00-A9E285CC46D0Q45870581-9928493E-67E5-4522-ABC5-D1F9347EB680Q46055970-43A15C8C-1E3F-449B-8BFB-DEC36E75F84AQ47136959-ADBCFFF9-A3FC-4598-ABDE-9110B60FBC85Q48270481-246855D4-0D0E-42A2-9295-45F98B77CEAEQ50945737-2E409FFC-AF4D-4791-AF95-AF0E59CBA45FQ51232163-7349D886-8EF5-47F0-9387-DE7C1E2E7CD8Q52671903-0B7AF10E-5A03-46C1-8CB7-E0683D537E4CQ53963822-8E6339E7-A609-4E7A-B694-9047B9376DB8
P2860
Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Posttranscriptional regulation ...... or-stimulated splenic B cells.
@ast
Posttranscriptional regulation ...... or-stimulated splenic B cells.
@en
type
label
Posttranscriptional regulation ...... or-stimulated splenic B cells.
@ast
Posttranscriptional regulation ...... or-stimulated splenic B cells.
@en
prefLabel
Posttranscriptional regulation ...... or-stimulated splenic B cells.
@ast
Posttranscriptional regulation ...... or-stimulated splenic B cells.
@en
P2093
P2860
P356
P1476
Posttranscriptional regulation ...... or-stimulated splenic B cells.
@en
P2093
A B Satterthwaite
I L Weissman
S Nisitani
P2860
P304
P356
10.1073/PNAS.050583597
P407
P577
2000-03-01T00:00:00Z